ARRY-520 is a potent kinesin spindle protein inhibitor that caused marked tumor regression in preclinical models of human cancer at tolerated doses, often leading to complete, durable responses.
The trial, which will be conducted in the US, is designed to evaluate the safety, tolerability and pharmacokinetics of ARRY-520 following intravenous administration to patients with advanced cancer. In addition, the trial will examine indicators of therapeutic activity in these patients.
Kevin Koch, president and chief scientific officer, said: “We are pleased that ARRY-520 has advanced to the stage of treated cancer patients in a phase I clinical trial. We are looking forward to continued progress on ARRY-520, as well as our other nine development programs, during 2007.”